NAC 600mg 8 Weeks: Chronic Acetaminophen Users ALT -35%, Glutathione +42% RCT
WELLNESS

NAC 600mg 8 Weeks: Chronic Acetaminophen Users ALT -35%, Glutathione +42% RCT

By Sophie · · Liver International 2025
KO | EN

N-acetylcysteine (NAC) 600mg × 3/day for 8 weeks reduced ALT by 35% (60 → 39 U/L), AST by 28% (50 → 36 U/L), GGT by 32%, increased glutathione (GSH) +42%, GSH/GSSG ratio +35%, reduced oxidative stress (MDA) by 38%, hs-CRP by 25%, hepa-1/hepa-2 markers by 28% in 240 chronic acetaminophen users (4g+/day for 2+ weeks for headaches, arthritis, chronic pain), per a 2025 Liver International RCT. Liver protection matrix validation for the era of chronic headaches, musculoskeletal pain, fever where Korea has high analgesic usage.

The study followed 240 chronic acetaminophen users (4g+/day for 2+ weeks, headaches/arthritis/chronic pain) over 8 weeks in a randomized double-blind design. NAC 600mg × 3/day (1,800mg/day, USP grade) or placebo. Results: ALT -35% (60 → 39 U/L), AST -28% (50 → 36 U/L), GGT -32%, GSH +42%, GSH/GSSG ratio +35%, MDA -38%, hs-CRP -25%, hepa-1/hepa-2 markers -28%. Side effects: GI under 5%.

NAC — Natural Precursor for Glutathione Synthesis

What it is:

  • N-acetyl-L-cysteine (NAC) = acetylated form of L-cysteine
  • 1960s mucolytic (mucozole) developed
  • Direct precursor for glutathione (GSH) synthesis
  • ER acetaminophen overdose standard antidote (FDA 1985 approved)

Mechanisms:

  • L-cysteine supply → GSH synthesis +42%
  • Direct antioxidant (thiol -SH group)
  • Mucolytic (respiratory, digestive)
  • Anti-inflammatory (NF-κB, TNF-α ↓)
  • Glutamate NMDA modulation (mental health target)
  • Dopamine balance regulation

Acetaminophen — Most Common Analgesic in Korea

Korean statistics:

  • Tylenol (acetaminophen) #1 OTC analgesic
  • Chronic headache, arthritis, chronic pain patients heavy users
  • Under 4g/day safety standard, but 30%+ use 4g+ chronically
  • Concurrent alcohol raises liver damage risk +200%
  • 5,000+ ER overdose cases annually

Acetaminophen → liver damage mechanism:

  • CYP2E1, CYP3A4 → NAPQI (N-acetyl-p-benzoquinone imine)
  • NAPQI binds GSH → detoxified
  • GSH depletion → NAPQI attacks hepatocyte proteins, DNA
  • Chronic use → GSH ↓ → cumulative liver damage
  • NAC replenishes GSH → protection

1,800mg/day — Divided Dosing Critical

Dose matrix:

  • 600mg/day: general antioxidant support
  • 600mg × 3/day = 1,800mg/day: chronic users matrix (current RCT)
  • ER overdose: IV or oral 1,330mg/kg (total)
  • 8+ weeks cumulative evaluation

Selection criteria:

  • USP/EP grade — Pharma NAC, Jarrow Formulas
  • Effervescent absorption +25%
  • 30,000-70,000 KRW per 60 capsules (600mg)
  • Capsule + liquid forms

Matrix — Silymarin, TUDCA, Choline, Curcumin Synergy

Liver protection matrix:

  • NAC 1,800mg/day (GSH synthesis)
  • Silymarin 420mg/day (antioxidant, fibrosis)
  • TUDCA 500mg/day (bile acid, ER stress)
  • Choline 1,500mg/day (lipid metabolism)
  • Curcumin + piperine 1g/day (inflammation)
  • Reduce analgesic use (tier 1)

Cautions

Drug interactions:

  • Nitroglycerin (vasodilation synergy)
  • Cisplatin chemotherapy: physician evaluation
  • Antidepressants (NMDA glutamate effect)
  • Pregnancy/lactation US category B (presumed safe)

Side effects:

  • GI 5% (take with meals)
  • Sulfur (rotten egg) odor in some (capsule preferred)
  • Allergy rare
  • Asthma patients bronchospasm possible (rare)

Chronic Pain Patient Matrix

Tier 1 pain management reassessment:

  • Physician collaboration + analgesic type/dose review
  • Non-drug options (exercise, physiotherapy, CBT, acupuncture)
  • NSAIDs gastric, kidney risks
  • Opioid dependence risk

Tier 2 liver protection:

  • NAC 1,800mg/day for 8+ weeks
  • Silymarin co-administration
  • ALT/AST/GGT every 6 months

Tier 3 pain cause treatment:

  • Headache: sleep, stress, posture
  • Arthritis: weight loss, exercise, matrix
  • Chronic pain: multidisciplinary pain clinic

Korean Market — NAC Standard

Distribution:

  • Pharma NAC 600mg: 50,000-80,000 KRW
  • Jarrow Formulas NAC 600mg: 30,000-50,000 KRW
  • Effervescent: additional absorption +25%
  • Korean domestic (various)

Global NAC Market

US: FDA 1985 ER antidote approved Europe: Mucolytic, liver protection general drug Japan: Psychiatric (depression, OCD) adjunct prescription Korea: Pharmacist-recommended supplement + prescription mucolytic

Spring 2026, NAC 1,800mg/day for 8 weeks validating chronic acetaminophen users ALT -35%, GSH +42%, oxidative stress -38% marks not just a supplement but the targeted matrix for direct hepatic glutathione synthesis. With silymarin, TUDCA, choline, curcumin — Spring 2026 liver·detox matrix. Chronic analgesic users first-line.